1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Breakthrough Therapy (BT) Designation Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 Oncology 1.2.3 Infectious Diseases 1.2.4 Rare Diseases 1.2.5 Autoimmune Diseases 1.2.6 Pulmonary Diseases 1.2.7 Neurological Disorders 1.2.8 Others 1.3 Market by Application 1.3.1 Global Breakthrough Therapy (BT) Designation Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Hospital 1.3.3 Clinic 1.3.4 Research Institute 1.3.5 Laboratories 1.3.6 Others 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Breakthrough Therapy (BT) Designation Market Perspective (2016-2027) 2.2 Breakthrough Therapy (BT) Designation Growth Trends by Regions 2.2.1 Breakthrough Therapy (BT) Designation Market Size by Regions: 2016 VS 2021 VS 2027 2.2.2 Breakthrough Therapy (BT) Designation Historic Market Share by Regions (2016-2021) 2.2.3 Breakthrough Therapy (BT) Designation Forecasted Market Size by Regions (2022-2027) 2.3 Breakthrough Therapy (BT) Designation Industry Dynamic 2.3.1 Breakthrough Therapy (BT) Designation Market Trends 2.3.2 Breakthrough Therapy (BT) Designation Market Drivers 2.3.3 Breakthrough Therapy (BT) Designation Market Challenges 2.3.4 Breakthrough Therapy (BT) Designation Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Breakthrough Therapy (BT) Designation Players by Revenue 3.1.1 Global Top Breakthrough Therapy (BT) Designation Players by Revenue (2016-2021) 3.1.2 Global Breakthrough Therapy (BT) Designation Revenue Market Share by Players (2016-2021) 3.2 Global Breakthrough Therapy (BT) Designation Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by Breakthrough Therapy (BT) Designation Revenue 3.4 Global Breakthrough Therapy (BT) Designation Market Concentration Ratio 3.4.1 Global Breakthrough Therapy (BT) Designation Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Breakthrough Therapy (BT) Designation Revenue in 2020 3.5 Breakthrough Therapy (BT) Designation Key Players Head office and Area Served 3.6 Key Players Breakthrough Therapy (BT) Designation Product Solution and Service 3.7 Date of Enter into Breakthrough Therapy (BT) Designation Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Breakthrough Therapy (BT) Designation Breakdown Data by Type 4.1 Global Breakthrough Therapy (BT) Designation Historic Market Size by Type (2016-2021) 4.2 Global Breakthrough Therapy (BT) Designation Forecasted Market Size by Type (2022-2027) 5 Breakthrough Therapy (BT) Designation Breakdown Data by Application 5.1 Global Breakthrough Therapy (BT) Designation Historic Market Size by Application (2016-2021) 5.2 Global Breakthrough Therapy (BT) Designation Forecasted Market Size by Application (2022-2027) 6 North America 6.1 North America Breakthrough Therapy (BT) Designation Market Size (2016-2027) 6.2 North America Breakthrough Therapy (BT) Designation Market Size by Type 6.2.1 North America Breakthrough Therapy (BT) Designation Market Size by Type (2016-2021) 6.2.2 North America Breakthrough Therapy (BT) Designation Market Size by Type (2022-2027) 6.2.3 North America Breakthrough Therapy (BT) Designation Market Size by Type (2016-2027) 6.3 North America Breakthrough Therapy (BT) Designation Market Size by Application 6.3.1 North America Breakthrough Therapy (BT) Designation Market Size by Application (2016-2021) 6.3.2 North America Breakthrough Therapy (BT) Designation Market Size by Application (2022-2027) 6.3.3 North America Breakthrough Therapy (BT) Designation Market Size by Application (2016-2027) 6.4 North America Breakthrough Therapy (BT) Designation Market Size by Country 6.4.1 North America Breakthrough Therapy (BT) Designation Market Size by Country (2016-2021) 6.4.2 North America Breakthrough Therapy (BT) Designation Market Size by Country (2022-2027) 6.4.3 United States 6.4.4 Canada 7 Europe 7.1 Europe Breakthrough Therapy (BT) Designation Market Size (2016-2027) 7.2 Europe Breakthrough Therapy (BT) Designation Market Size by Type 7.2.1 Europe Breakthrough Therapy (BT) Designation Market Size by Type (2016-2021) 7.2.2 Europe Breakthrough Therapy (BT) Designation Market Size by Type (2022-2027) 7.2.3 Europe Breakthrough Therapy (BT) Designation Market Size by Type (2016-2027) 7.3 Europe Breakthrough Therapy (BT) Designation Market Size by Application 7.3.1 Europe Breakthrough Therapy (BT) Designation Market Size by Application (2016-2021) 7.3.2 Europe Breakthrough Therapy (BT) Designation Market Size by Application (2022-2027) 7.3.3 Europe Breakthrough Therapy (BT) Designation Market Size by Application (2016-2027) 7.4 Europe Breakthrough Therapy (BT) Designation Market Size by Country 7.4.1 Europe Breakthrough Therapy (BT) Designation Market Size by Country (2016-2021) 7.4.2 Europe Breakthrough Therapy (BT) Designation Market Size by Country (2022-2027) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic 8 Asia-Pacific 8.1 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size (2016-2027) 8.2 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Type 8.2.1 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Type (2016-2021) 8.2.2 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Type (2022-2027) 8.2.3 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Type (2016-2027) 8.3 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Application 8.3.1 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Application (2016-2021) 8.3.2 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Application (2022-2027) 8.3.3 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Application (2016-2027) 8.4 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Region 8.4.1 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Region (2016-2021) 8.4.2 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Region (2022-2027) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Breakthrough Therapy (BT) Designation Market Size (2016-2027) 9.2 Latin America Breakthrough Therapy (BT) Designation Market Size by Type 9.2.1 Latin America Breakthrough Therapy (BT) Designation Market Size by Type (2016-2021) 9.2.2 Latin America Breakthrough Therapy (BT) Designation Market Size by Type (2022-2027) 9.2.3 Latin America Breakthrough Therapy (BT) Designation Market Size by Type (2016-2027) 9.3 Latin America Breakthrough Therapy (BT) Designation Market Size by Application 9.3.1 Latin America Breakthrough Therapy (BT) Designation Market Size by Application (2016-2021) 9.3.2 Latin America Breakthrough Therapy (BT) Designation Market Size by Application (2022-2027) 9.3.3 Latin America Breakthrough Therapy (BT) Designation Market Size by Application (2016-2027) 9.4 Latin America Breakthrough Therapy (BT) Designation Market Size by Country 9.4.1 Latin America Breakthrough Therapy (BT) Designation Market Size by Country (2016-2021) 9.4.2 Latin America Breakthrough Therapy (BT) Designation Market Size by Country (2022-2027) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size (2016-2027) 10.2 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Type 10.2.1 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Type (2016-2021) 10.2.2 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Type (2022-2027) 10.2.3 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Type (2016-2027) 10.3 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Application 10.3.1 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Application (2016-2021) 10.3.2 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Application (2022-2027) 10.3.3 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Application (2016-2027) 10.4 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Country 10.4.1 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Country (2016-2021) 10.4.2 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Country (2022-2027) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 Roche 11.1.1 Roche Company Details 11.1.2 Roche Business Overview 11.1.3 Roche Breakthrough Therapy (BT) Designation Introduction 11.1.4 Roche Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) 11.1.5 Roche Recent Development 11.2 Abbvie 11.2.1 Abbvie Company Details 11.2.2 Abbvie Business Overview 11.2.3 Abbvie Breakthrough Therapy (BT) Designation Introduction 11.2.4 Abbvie Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) 11.2.5 Abbvie Recent Development 11.3 Novartis International AG 11.3.1 Novartis International AG Company Details 11.3.2 Novartis International AG Business Overview 11.3.3 Novartis International AG Breakthrough Therapy (BT) Designation Introduction 11.3.4 Novartis International AG Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) 11.3.5 Novartis International AG Recent Development 11.4 Janssen 11.4.1 Janssen Company Details 11.4.2 Janssen Business Overview 11.4.3 Janssen Breakthrough Therapy (BT) Designation Introduction 11.4.4 Janssen Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) 11.4.5 Janssen Recent Development 11.5 BMS 11.5.1 BMS Company Details 11.5.2 BMS Business Overview 11.5.3 BMS Breakthrough Therapy (BT) Designation Introduction 11.5.4 BMS Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) 11.5.5 BMS Recent Development 11.6 Eli Lilly 11.6.1 Eli Lilly Company Details 11.6.2 Eli Lilly Business Overview 11.6.3 Eli Lilly Breakthrough Therapy (BT) Designation Introduction 11.6.4 Eli Lilly Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) 11.6.5 Eli Lilly Recent Development 11.7 Gilead 11.7.1 Gilead Company Details 11.7.2 Gilead Business Overview 11.7.3 Gilead Breakthrough Therapy (BT) Designation Introduction 11.7.4 Gilead Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) 11.7.5 Gilead Recent Development 11.8 Sanofi 11.8.1 Sanofi Company Details 11.8.2 Sanofi Business Overview 11.8.3 Sanofi Breakthrough Therapy (BT) Designation Introduction 11.8.4 Sanofi Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) 11.8.5 Sanofi Recent Development 11.9 Regeneron 11.9.1 Regeneron Company Details 11.9.2 Regeneron Business Overview 11.9.3 Regeneron Breakthrough Therapy (BT) Designation Introduction 11.9.4 Regeneron Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) 11.9.5 Regeneron Recent Development 11.10 Acadia 11.10.1 Acadia Company Details 11.10.2 Acadia Business Overview 11.10.3 Acadia Breakthrough Therapy (BT) Designation Introduction 11.10.4 Acadia Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) 11.10.5 Acadia Recent Development 11.11 Boehringer Ingelheim 11.11.1 Boehringer Ingelheim Company Details 11.11.2 Boehringer Ingelheim Business Overview 11.11.3 Boehringer Ingelheim Breakthrough Therapy (BT) Designation Introduction 11.11.4 Boehringer Ingelheim Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) 11.11.5 Boehringer Ingelheim Recent Development 11.12 Amgen 11.12.1 Amgen Company Details 11.12.2 Amgen Business Overview 11.12.3 Amgen Breakthrough Therapy (BT) Designation Introduction 11.12.4 Amgen Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) 11.12.5 Amgen Recent Development 11.13 AstraZeneca 11.13.1 AstraZeneca Company Details 11.13.2 AstraZeneca Business Overview 11.13.3 AstraZeneca Breakthrough Therapy (BT) Designation Introduction 11.13.4 AstraZeneca Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) 11.13.5 AstraZeneca Recent Development 11.14 GlaxoSmithKline 11.14.1 GlaxoSmithKline Company Details 11.14.2 GlaxoSmithKline Business Overview 11.14.3 GlaxoSmithKline Breakthrough Therapy (BT) Designation Introduction 11.14.4 GlaxoSmithKline Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) 11.14.5 GlaxoSmithKline Recent Development 11.15 Vertex 11.15.1 Vertex Company Details 11.15.2 Vertex Business Overview 11.15.3 Vertex Breakthrough Therapy (BT) Designation Introduction 11.15.4 Vertex Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) 11.15.5 Vertex Recent Development 11.16 Alexion 11.16.1 Alexion Company Details 11.16.2 Alexion Business Overview 11.16.3 Alexion Breakthrough Therapy (BT) Designation Introduction 11.16.4 Alexion Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) 11.16.5 Alexion Recent Development 11.17 Merck 11.17.1 Merck Company Details 11.17.2 Merck Business Overview 11.17.3 Merck Breakthrough Therapy (BT) Designation Introduction 11.17.4 Merck Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) 11.17.5 Merck Recent Development 11.18 Jazz Pharmaceuticals 11.18.1 Jazz Pharmaceuticals Company Details 11.18.2 Jazz Pharmaceuticals Business Overview 11.18.3 Jazz Pharmaceuticals Breakthrough Therapy (BT) Designation Introduction 11.18.4 Jazz Pharmaceuticals Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) 11.18.5 Jazz Pharmaceuticals Recent Development 11.18 Exelixis .1 Exelixis Company Details .2 Exelixis Business Overview .3 Exelixis Breakthrough Therapy (BT) Designation Introduction .4 Exelixis Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) .5 Exelixis Recent Development 11.20 Eisai 11.20.1 Eisai Company Details 11.20.2 Eisai Business Overview 11.20.3 Eisai Breakthrough Therapy (BT) Designation Introduction 11.20.4 Eisai Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) 11.20.5 Eisai Recent Development 11.21 Takeda 11.21.1 Takeda Company Details 11.21.2 Takeda Business Overview 11.21.3 Takeda Breakthrough Therapy (BT) Designation Introduction 11.21.4 Takeda Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) 11.21.5 Takeda Recent Development 11.22 Pfizer 11.22.1 Pfizer Company Details 11.22.2 Pfizer Business Overview 11.22.3 Pfizer Breakthrough Therapy (BT) Designation Introduction 11.22.4 Pfizer Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) 11.22.5 Pfizer Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Breakthrough Therapy (BT) Designation Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027 Table 2. Key Players of Oncology Table 3. Key Players of Infectious Diseases Table 4. Key Players of Rare Diseases Table 5. Key Players of Autoimmune Diseases Table 6. Key Players of Pulmonary Diseases Table 7. Key Players of Neurological Disorders Table 8. Key Players of Others Table 9. Global Breakthrough Therapy (BT) Designation Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027 Table 10. Global Breakthrough Therapy (BT) Designation Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027 Table 11. Global Breakthrough Therapy (BT) Designation Market Size by Regions (2016-2021) & (US$ Million) Table 12. Global Breakthrough Therapy (BT) Designation Market Share by Regions (2016-2021) Table 13. Global Breakthrough Therapy (BT) Designation Forecasted Market Size by Regions (2022-2027) & (US$ Million) Table 14. Global Breakthrough Therapy (BT) Designation Market Share by Regions (2022-2027) Table 15. Breakthrough Therapy (BT) Designation Market Trends Table 16. Breakthrough Therapy (BT) Designation Market Drivers Table 17. Breakthrough Therapy (BT) Designation Market Challenges Table 18. Breakthrough Therapy (BT) Designation Market Restraints Table 19. Global Breakthrough Therapy (BT) Designation Revenue by Players (2016-2021) & (US$ Million) Table 20. Global Breakthrough Therapy (BT) Designation Market Share by Players (2016-2021) Table 21. Global Top Breakthrough Therapy (BT) Designation Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Breakthrough Therapy (BT) Designation as of 2020) Table 22. Ranking of Global Top Breakthrough Therapy (BT) Designation Companies by Revenue (US$ Million) in 2020 Table 23. Global 5 Largest Players Market Share by Breakthrough Therapy (BT) Designation Revenue (CR5 and HHI) & (2016-2021) Table 24. Key Players Headquarters and Area Served Table 25. Key Players Breakthrough Therapy (BT) Designation Product Solution and Service Table 26. Date of Enter into Breakthrough Therapy (BT) Designation Market Table 27. Mergers & Acquisitions, Expansion Plans Table 28. Global Breakthrough Therapy (BT) Designation Market Size by Type (2016-2021) (US$ Million) Table 29. Global Breakthrough Therapy (BT) Designation Revenue Market Share by Type (2016-2021) Table 30. Global Breakthrough Therapy (BT) Designation Forecasted Market Size by Type (2022-2027) (US$ Million) Table 31. Global Breakthrough Therapy (BT) Designation Revenue Market Share by Type (2022-2027) & (US$ Million) Table 32. Global Breakthrough Therapy (BT) Designation Market Size Share by Application (2016-2021) & (US$ Million) Table 33. Global Breakthrough Therapy (BT) Designation Revenue Market Share by Application (2016-2021) Table 34. Global Breakthrough Therapy (BT) Designation Forecasted Market Size by Application (2022-2027) (US$ Million) Table 35. Global Breakthrough Therapy (BT) Designation Revenue Market Share by Application (2022-2027) & (US$ Million) Table 36. North America Breakthrough Therapy (BT) Designation Market Size by Type (2016-2021) (US$ Million) Table 37. North America Breakthrough Therapy (BT) Designation Market Size by Type (2022-2027) & (US$ Million) Table 38. North America Breakthrough Therapy (BT) Designation Market Size by Application (2016-2021) (US$ Million) Table 39. North America Breakthrough Therapy (BT) Designation Market Size by Application (2022-2027) & (US$ Million) Table 40. North America Breakthrough Therapy (BT) Designation Market Size by Country (2016-2021) & (US$ Million) Table 41. North America Breakthrough Therapy (BT) Designation Market Size by Country (2022-2027) & (US$ Million) Table 42. Europe Breakthrough Therapy (BT) Designation Market Size by Type (2016-2021) (US$ Million) Table 43. Europe Breakthrough Therapy (BT) Designation Market Size by Type (2022-2027) & (US$ Million) Table 44. Europe Breakthrough Therapy (BT) Designation Market Size by Application (2016-2021) (US$ Million) Table 45. Europe Breakthrough Therapy (BT) Designation Market Size by Application (2022-2027) & (US$ Million) Table 46. Europe Breakthrough Therapy (BT) Designation Market Size by Country (2016-2021) & (US$ Million) Table 47. Europe Breakthrough Therapy (BT) Designation Market Size by Country (2022-2027) & (US$ Million) Table 48. Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Type (2016-2021) (US$ Million) Table 49. Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Type (2022-2027) & (US$ Million) Table 50. Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Application (2016-2021) (US$ Million) Table 51. Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Application (2022-2027) & (US$ Million) Table 52. Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Region (2016-2021) & (US$ Million) Table 53. Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Region (2022-2027) & (US$ Million) Table 54. Latin America Breakthrough Therapy (BT) Designation Market Size by Type (2016-2021) (US$ Million) Table 55. Latin America Breakthrough Therapy (BT) Designation Market Size by Type (2022-2027) & (US$ Million) Table 56. Latin America Breakthrough Therapy (BT) Designation Market Size by Application (2016-2021) (US$ Million) Table 57. Latin America Breakthrough Therapy (BT) Designation Market Size by Application (2022-2027) & (US$ Million) Table 58. Latin America Breakthrough Therapy (BT) Designation Market Size by Country (2016-2021) & (US$ Million) Table 59. Latin America Breakthrough Therapy (BT) Designation Market Size by Country (2022-2027) & (US$ Million) Table 60. Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Type (2016-2021) (US$ Million) Table 61. Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Type (2022-2027) & (US$ Million) Table 62. Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Application (2016-2021) (US$ Million) Table 63. Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Application (2022-2027) & (US$ Million) Table 64. Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Country (2016-2021) & (US$ Million) Table 65. Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Country (2022-2027) & (US$ Million) Table 66. Roche Company Details Table 67. Roche Business Overview Table 68. Roche Breakthrough Therapy (BT) Designation Product Table 69. Roche Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) & (US$ Million) Table 70. Roche Recent Development Table 71. Abbvie Company Details Table 72. Abbvie Business Overview Table 73. Abbvie Breakthrough Therapy (BT) Designation Product Table 74. Abbvie Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) & (US$ Million) Table 75. Abbvie Recent Development Table 76. Novartis International AG Company Details Table 77. Novartis International AG Business Overview Table 78. Novartis International AG Breakthrough Therapy (BT) Designation Product Table 79. Novartis International AG Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) & (US$ Million) Table 80. Novartis International AG Recent Development Table 81. Janssen Company Details Table 82. Janssen Business Overview Table 83. Janssen Breakthrough Therapy (BT) Designation Product Table 84. Janssen Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) & (US$ Million) Table 85. Janssen Recent Development Table 86. BMS Company Details Table 87. BMS Business Overview Table 88. BMS Breakthrough Therapy (BT) Designation Product Table 89. BMS Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) & (US$ Million) Table 90. BMS Recent Development Table 91. Eli Lilly Company Details Table 92. Eli Lilly Business Overview Table 93. Eli Lilly Breakthrough Therapy (BT) Designation Product Table 94. Eli Lilly Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) & (US$ Million) Table 95. Eli Lilly Recent Development Table 96. Gilead Company Details Table 97. Gilead Business Overview Table 98. Gilead Breakthrough Therapy (BT) Designation Product Table 99. Gilead Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) & (US$ Million) Table 100. Gilead Recent Development Table 101. Sanofi Company Details Table 102. Sanofi Business Overview Table 103. Sanofi Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) & (US$ Million) Table 104. Sanofi Recent Development Table 105. Regeneron Company Details Table 106. Regeneron Business Overview Table 107. Regeneron Breakthrough Therapy (BT) Designation Product Table 108. Regeneron Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) & (US$ Million) Table 109. Regeneron Recent Development Table 110. Acadia Company Details Table 111. Acadia Business Overview Table 112. Acadia Breakthrough Therapy (BT) Designation Product Table 113. Acadia Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) & (US$ Million) Table 114. Acadia Recent Development Table 115. Boehringer Ingelheim Company Details Table 116. Boehringer Ingelheim Business Overview Table 117. Boehringer Ingelheim Breakthrough Therapy (BT) Designation Product Table 118. Boehringer Ingelheim Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) & (US$ Million) Table 119. Boehringer Ingelheim Recent Development Table 120. Amgen Company Details Table 121. Amgen Business Overview Table 122. Amgen Breakthrough Therapy (BT) Designation Product Table 123. Amgen Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) & (US$ Million) Table 124. Amgen Recent Development Table 125. AstraZeneca Company Details Table 126. AstraZeneca Business Overview Table 127. AstraZeneca Breakthrough Therapy (BT) Designation Product Table 128. AstraZeneca Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) & (US$ Million) Table 129. AstraZeneca Recent Development Table 130. GlaxoSmithKline Company Details Table 131. GlaxoSmithKline Business Overview Table 132. GlaxoSmithKline Breakthrough Therapy (BT) Designation Product Table 133. GlaxoSmithKline Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) & (US$ Million) Table 134. GlaxoSmithKline Recent Development Table 135. Vertex Company Details Table 136. Vertex Business Overview Table 137. Vertex Breakthrough Therapy (BT) Designation Product Table 138. Vertex Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) & (US$ Million) Table 139. Vertex Recent Development Table 140. Alexion Company Details Table 141. Alexion Business Overview Table 142. Alexion Breakthrough Therapy (BT) Designation Product Table 143. Alexion Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) & (US$ Million) Table 144. Alexion Recent Development Table 145. Merck Company Details Table 146. Merck Business Overview Table 147. Merck Breakthrough Therapy (BT) Designation Product Table 148. Merck Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) & (US$ Million) Table 149. Merck Recent Development Table 150. Jazz Pharmaceuticals Company Details Table 151. Jazz Pharmaceuticals Business Overview Table 152. Jazz Pharmaceuticals Breakthrough Therapy (BT) Designation Product Table 153. Jazz Pharmaceuticals Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) & (US$ Million) Table 154. Jazz Pharmaceuticals Recent Development Table 155. Exelixis Company Details Table 156. Exelixis Business Overview Table 157. Exelixis Breakthrough Therapy (BT) Designation Product Table 158. Exelixis Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) & (US$ Million) Table 159. Exelixis Recent Development Table 160. Eisai Company Details Table 161. Eisai Business Overview Table 162. Eisai Breakthrough Therapy (BT) Designation Product Table 163. Eisai Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) & (US$ Million) Table 164. Eisai Recent Development Table 165. Takeda Company Details Table 166. Takeda Business Overview Table 167. Takeda Breakthrough Therapy (BT) Designation Product Table 168. Takeda Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) & (US$ Million) Table 169. Takeda Recent Development Table 170. Pfizer Company Details Table 171. Pfizer Business Overview Table 172. Pfizer Breakthrough Therapy (BT) Designation Product Table 173. Pfizer Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021) & (US$ Million) Table 174. Pfizer Recent Development Table 175. Research Programs/Design for This Report Table 176. Key Data Information from Secondary Sources Table 177. Key Data Information from Primary Sources List of Figures Figure 1. Global Breakthrough Therapy (BT) Designation Market Share by Type: 2020 VS 2027 Figure 2. Oncology Features Figure 3. Infectious Diseases Features Figure 4. Rare Diseases Features Figure 5. Autoimmune Diseases Features Figure 6. Pulmonary Diseases Features Figure 7. Neurological Disorders Features Figure 8. Others Features Figure 9. Global Breakthrough Therapy (BT) Designation Market Share by Application: 2020 VS 2027 Figure 10. Hospital Case Studies Figure 11. Clinic Case Studies Figure 12. Research Institute Case Studies Figure 13. Laboratories Case Studies Figure 14. Others Case Studies Figure 15. Breakthrough Therapy (BT) Designation Report Years Considered Figure 16. Global Breakthrough Therapy (BT) Designation Market Size (US$ Million), Year-over-Year: 2016-2027 Figure 17. Global Breakthrough Therapy (BT) Designation Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 18. Global Breakthrough Therapy (BT) Designation Market Share by Regions: 2020 VS 2027 Figure 19. Global Breakthrough Therapy (BT) Designation Market Share by Regions (2022-2027) Figure 20. Global Breakthrough Therapy (BT) Designation Market Share by Players in 2020 Figure 21. Global Top Breakthrough Therapy (BT) Designation Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Breakthrough Therapy (BT) Designation as of 2020 Figure 22. The Top 10 and 5 Players Market Share by Breakthrough Therapy (BT) Designation Revenue in 2020 Figure 23. Global Breakthrough Therapy (BT) Designation Revenue Market Share by Type (2016-2021) Figure 24. Global Breakthrough Therapy (BT) Designation Revenue Market Share by Type (2022-2027) Figure 25. North America Breakthrough Therapy (BT) Designation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 26. North America Breakthrough Therapy (BT) Designation Market Share by Type (2016-2027) Figure 27. North America Breakthrough Therapy (BT) Designation Market Share by Application (2016-2027) Figure 28. North America Breakthrough Therapy (BT) Designation Market Share by Country (2016-2027) Figure 29. United States Breakthrough Therapy (BT) Designation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 30. Canada Breakthrough Therapy (BT) Designation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 31. Europe Breakthrough Therapy (BT) Designation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 32. Europe Breakthrough Therapy (BT) Designation Market Share by Type (2016-2027) Figure 33. Europe Breakthrough Therapy (BT) Designation Market Share by Application (2016-2027) Figure 34. Europe Breakthrough Therapy (BT) Designation Market Share by Country (2016-2027) Figure 35. Germany Breakthrough Therapy (BT) Designation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 36. France Breakthrough Therapy (BT) Designation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 37. U.K. Breakthrough Therapy (BT) Designation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 38. Italy Breakthrough Therapy (BT) Designation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 39. Russia Breakthrough Therapy (BT) Designation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 40. Nordic Breakthrough Therapy (BT) Designation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 41. Asia-Pacific Breakthrough Therapy (BT) Designation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 42. Asia-Pacific Breakthrough Therapy (BT) Designation Market Share by Type (2016-2027) Figure 43. Asia-Pacific Breakthrough Therapy (BT) Designation Market Share by Application (2016-2027) Figure 44. Asia-Pacific Breakthrough Therapy (BT) Designation Market Share by Region (2016-2027) Figure 45. China Breakthrough Therapy (BT) Designation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 46. Japan Breakthrough Therapy (BT) Designation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 47. South Korea Breakthrough Therapy (BT) Designation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 48. Southeast Asia Breakthrough Therapy (BT) Designation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 49. India Breakthrough Therapy (BT) Designation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 50. Australia Breakthrough Therapy (BT) Designation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 51. Latin America Breakthrough Therapy (BT) Designation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 52. Latin America Breakthrough Therapy (BT) Designation Market Share by Type (2016-2027) Figure 53. Latin America Breakthrough Therapy (BT) Designation Market Share by Application (2016-2027) Figure 54. Latin America Breakthrough Therapy (BT) Designation Market Share by Country (2016-2027) Figure 55. Mexico Breakthrough Therapy (BT) Designation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 56. Brazil Breakthrough Therapy (BT) Designation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 57. Middle East & Africa Breakthrough Therapy (BT) Designation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 58. Middle East & Africa Breakthrough Therapy (BT) Designation Market Share by Type (2016-2027) Figure 59. Middle East & Africa Breakthrough Therapy (BT) Designation Market Share by Application (2016-2027) Figure 60. Middle East & Africa Breakthrough Therapy (BT) Designation Market Share by Country (2016-2027) Figure 61. Turkey Breakthrough Therapy (BT) Designation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 62. Saudi Arabia Breakthrough Therapy (BT) Designation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 63. UAE Breakthrough Therapy (BT) Designation Market Size YoY Growth (2016-2027) & (US$ Million) Figure 64. Roche Revenue Growth Rate in Breakthrough Therapy (BT) Designation Business (2016-2021) Figure 65. Abbvie Revenue Growth Rate in Breakthrough Therapy (BT) Designation Business (2016-2021) Figure 66. Novartis International AG Revenue Growth Rate in Breakthrough Therapy (BT) Designation Business (2016-2021) Figure 67. Janssen Revenue Growth Rate in Breakthrough Therapy (BT) Designation Business (2016-2021) Figure 68. BMS Revenue Growth Rate in Breakthrough Therapy (BT) Designation Business (2016-2021) Figure 69. Eli Lilly Revenue Growth Rate in Breakthrough Therapy (BT) Designation Business (2016-2021) Figure 70. Gilead Revenue Growth Rate in Breakthrough Therapy (BT) Designation Business (2016-2021) Figure 71. Sanofi Revenue Growth Rate in Breakthrough Therapy (BT) Designation Business (2016-2021) Figure 72. Regeneron Revenue Growth Rate in Breakthrough Therapy (BT) Designation Business (2016-2021) Figure 73. Acadia Revenue Growth Rate in Breakthrough Therapy (BT) Designation Business (2016-2021) Figure 74. Boehringer Ingelheim Revenue Growth Rate in Breakthrough Therapy (BT) Designation Business (2016-2021) Figure 75. Amgen Revenue Growth Rate in Breakthrough Therapy (BT) Designation Business (2016-2021) Figure 76. AstraZeneca Revenue Growth Rate in Breakthrough Therapy (BT) Designation Business (2016-2021) Figure 77. GlaxoSmithKline Revenue Growth Rate in Breakthrough Therapy (BT) Designation Business (2016-2021) Figure 78. Vertex Revenue Growth Rate in Breakthrough Therapy (BT) Designation Business (2016-2021) Figure 79. Alexion Revenue Growth Rate in Breakthrough Therapy (BT) Designation Business (2016-2021) Figure 80. Merck Revenue Growth Rate in Breakthrough Therapy (BT) Designation Business (2016-2021) Figure 81. Jazz Pharmaceuticals Revenue Growth Rate in Breakthrough Therapy (BT) Designation Business (2016-2021) Figure 82. Exelixis Revenue Growth Rate in Breakthrough Therapy (BT) Designation Business (2016-2021) Figure 83. Eisai Revenue Growth Rate in Breakthrough Therapy (BT) Designation Business (2016-2021) Figure 84. Takeda Revenue Growth Rate in Breakthrough Therapy (BT) Designation Business (2016-2021) Figure 85. Pfizer Revenue Growth Rate in Breakthrough Therapy (BT) Designation Business (2016-2021) Figure 86. Bottom-up and Top-down Approaches for This Report Figure 87. Data Triangulation Figure 88. Key Executives Interviewed

Roche Abbvie Novartis International AG Janssen BMS Eli Lilly Gilead Sanofi Regeneron Acadia Boehringer Ingelheim Amgen AstraZeneca GlaxoSmithKline Vertex Alexion Merck Jazz Pharmaceuticals Exelixis Eisai Takeda Pfizer